TCTimothy Cardozo

Timothy Cardozo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy Cardozo has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • James Swetnam

    Google Inc., Mountain View CA, USA

    7 shared publications
  • Susan Zolla-Pazner

    Department of Pathology, New York University School of Medicine (NYSoM), New York, NY 10016, USA

    5 shared publications
  • Anna Gutowska

    Animal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, USA

    4 shared publications
  • Doreen Tivon

    GeneCentrix Inc. New York NY USA

    4 shared publications
  • Evgeny Shmelkov

    Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America

    4 shared publications
  • Genoveffa Franchini

    Animal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, USA

    4 shared publications

Latest Publications

  • Open Access

    Historeceptomics Profiling of Ketamine

    by Eric Rosenn, Harrison Agnor, Jennifer Fuller, Timothy Cardozo

    Ketamine elicits distinctive neuropsychiatric phenotypes from a complex and as yet elusive mechanism of action. Here, we applied an updated Historeceptomics approach to identify molecular targets and brain tissues that may contribute to its antidepressant, analgesic, and dissociative effects. Historeceptomics generates multidimensional target-tissue fingerprints by integrating drug-target activity with tissue-specific target expression, providing an anatomic profile of drug action. The results suggest that ketamine activity on NMDA receptors in the prefrontal and cingulate cortices and the amygdala may contribute to ketamine improvements in social functioning for MDD. However, this same receptor-tissue activity may invoke hallucinatory effects at higher intensity or with engagement of additional brain regions. The central nervous system (CNS) fingerprint for ketamine was compared with those of other psychoactive drugs, showing overlap with fingerprints from other antidepressant, hallucinogenic, and analgesic drugs. Some ketamine effects may be traced to specific enantiomers or metabolites of ketamine. These findings provide new insights into the mechanisms by which ketamine elicits its unique phenotype and demonstrate the utility of using Historeceptomics to understand complex drug action.

  • Open Access

    HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques

    by Massimiliano Bissa, Mohammad Arif Rahman, Luca Schifanella, Katherine C. Goldfarbmuren, Isabela Silva de Castro, Emmanuel K. Woode, Anna Gutowska, Melvin N. Doster, Sophia Brown, Sarkis Sarkis, et al.

    Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal infection with SIVmac251 or Simian-Human immunodeficiency virus, respectively. Adding the Army Liposome Formulation + QS21 (ALFQ) adjuvant to the ΔV1gp120+Alum boost (ALFQA) may enhance protective immune responses. Here, we show that ALFQA protects 58% of female macaques from infection following eleven exposures to SIVmac251, achieving 79% vaccine efficacy. The ALFQA vaccine regimen augments mucosal CD73+CD163+ M2-like macrophages and NKp44+ innate lymphoid cells (ILCs), while reducing NKG2A-NKP44- cells producing interferon-γ. Antibody-Dependent Cellular Cytotoxicity (ADCC) targeting helical V2, and mucosal tolerogenic dendritic cells-10 (DC-10) and envelope-specific interleukin-17+ NKp44+ ILCs, correlate with decreased risk of infection. Plasma proteome analysis links vaccine efficacy to lymphotoxin-α, mucosal DC-10, and chemokine (C-C motif) ligand-8, a chemokine produced mainly by M2-macrophages. These data support the role of pro-resolution immunity in protection afforded by the V1-deleted SIV and HIV immunogens. The Combined Long-term Efferocytosis and ADCC Responses (CLEAR) phase I HIV-vaccine trial is designed to test the safety and immunogenicity of the Alum and ALFQA adjuvants in combination with V1-deleted HIV immunogens in humans.


  • Open Access

    Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response

    by Mohammad Arif Rahman, Massimiliano Bissa, Hanna Scinto, Savannah E. Howe, Sarkis Sarkis, Zhong-Min Ma, Anna Gutowska, Xunqing Jiang, Christina C. Luo, Luca Schifanella, et al.

    Systemic vaccination of macaques with V1-deleted (ΔV1) envelope immunogens reduce the risk of SIVmac251 acquisition by approximately 60%, with protective roles played by V2-specific ADCC and envelope-specific mucosal IL-17+NKp44+ innate lymphoid cells (ILCs). We investigated whether increased mucosal responses to V2 benefit vaccine efficacy by delivering oral nanoparticles (NPs) that release V2-scaffolded on Typhoid Toxin B (TTB) to the large intestine. Strikingly, mucosal immunization of male macaques abrogated vaccine efficacy with control TTB or empty NPs, but vaccine efficacy of up to 47.6% was preserved with V2-TTB NPs. The deleterious effects of NPs were linked to preferential recruitment of mucosal plasmacytoid dendritic cells (pDCs), reduction of protective mucosal NKp44+ ILCs, increased non-protective mucosal PMA/Ionomycin-induced IFN-γ+NKG2A-NKp44-ILCs, and increased levels of mucosal activated Ki67+CD4+ T cells, a potential target for virus infection. V2-TTB NP mucosal boosting rescued vaccine efficacy, likely via high avidity V2-specific antibodies mediating ADCC, and higher frequencies of mucosal NKp44+ ILCs and of ∆V1gp120 binding antibody-secreting B cells in the rectal mucosa. These findings emphasize the central role of systemic immunization and mucosal V2-specific antibodies in the protection afforded by ΔV1 envelope immunogens and encourage careful evaluation of vaccine delivery platforms to avoid inducing immune responses favorable to HIV transmission.


  • Open Access

    Publisher Correction: Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques

    by Mohammad Arif Rahman, Massimiliano Bissa, Isabela Silva de Castro, Sabrina Helmold Hait, James D. Stamos, Farzana Bhuyan, Ruth Hunegnaw, Sarkis Sarkis, Anna Gutowska, Melvin N. Doster, et al.

  • Open Access

    Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques

    by Mohammad Arif Rahman, Massimiliano Bissa, Isabela Silva de Castro, Sabrina Helmold Hait, James D. Stamos, Farzana Bhuyan, Ruth Hunegnaw, Sarkis Sarkis, Anna Gutowska, Melvin N. Doster, et al.

    The human immunodeficiency virus epidemic continues in sub-Saharan Africa, and particularly affects adolescent girls and women who have limited access to antiretroviral therapy. Here we report that the risk of vaginal simian immunodeficiency virus (SIV)mac251 acquisition is reduced by more than 90% using a combination of a vaccine comprising V1-deleted (V2 enhanced) SIV envelope immunogens with topical treatment of the zinc-finger inhibitor SAMT-247. Following 14 weekly intravaginal exposures to the highly pathogenic SIVmac251, 80% of a cohort of 20 macaques vaccinated and treated with SAMT-247 remained uninfected. In an arm of 18 vaccinated-only animals without microbicide, 40% of macaques remained uninfected. The combined SAMT-247/vaccine regimen was significantly more effective than vaccination alone. By analysing immune correlates of protection, we show that, by increasing zinc availability, SAMT-247 increases natural killer cytotoxicity and monocyte efferocytosis, and decreases T-cell activation to augment vaccine-induced protection.


  • Open Access

    Conformational change of the Bordetella response regulator BvgA accompanies its activation of the B. pertussis virulence gene fhaB

    by David Kim, John Tracey, Manuel Becerra Flores, Kanita Chaudhry, Rafae Nasim, Abraham Correa-Medina, Leslie Knipling, Qing Chen, Scott Stibitz, Lisa M.M. Jenkins, et al.

    The BvgAS two-component system regulates virulence gene expression in Bordetella pertussis. Although precise three-dimensional structural information is not available for the response regulator BvgA, its sequence conservation with E. coli NarL and previous studies have indicated that it is composed of 3 domains: an N-terminal domain (NTD) containing the phosphorylation site, a linker, and a DNA-binding C-terminal domain (CTD). Previous work has determined how BvgACTD dimers interact with the promoter (PfhaB) of fhaB, the gene encoding the virulence adhesin filamentous hemagglutinin. Here we use molecular modeling, FeBABE footprinting, and crosslinking to show that within the transcription complex of phosphorylated BvgA (BvgA ∼ P), B. pertussis RNAP, and PfhaB, the NTDs displace from the CTDs and are positioned at specific locations relative to the three BvgA ∼ P binding sites. Our work identifies a patch of the NTD that faces the DNA and suggests that BvgA ∼ P undergoes a conformational rearrangement that relocates the NTD to allow productive interaction of the CTD with the DNA.

  • Open Access

    Regulated interaction of ID2 with the anaphase-promoting complex links progression through mitosis with reactivation of cell-type-specific transcription

    by Sang Bae Lee, Luciano Garofano, Aram Ko, Fulvio D’aNgelo, Brulinda Frangaj, Danika Sommer, Qiwen Gan, KyeongJin Kim, Timothy Cardozo, Antonio Iavarone, et al.

    Tissue-specific transcriptional activity is silenced in mitotic cells but it remains unclear whether the mitotic regulatory machinery interacts with tissue-specific transcriptional programs. We show that such cross-talk involves the controlled interaction between core subunits of the anaphase-promoting complex (APC) and the ID2 substrate. The N-terminus of ID2 is independently and structurally compatible with a pocket composed of core APC/C subunits that may optimally orient ID2 onto the APCCDH1 complex. Phosphorylation of serine-5 by CDK1 prevented the association of ID2 with core APC, impaired ubiquitylation and stabilized ID2 protein at the mitosis-G1 transition leading to inhibition of basic Helix-Loop-Helix (bHLH)-mediated transcription. The serine-5 phospho-mimetic mutant of ID2 that inefficiently bound core APC remained stable during mitosis, delayed exit from mitosis and reloading of bHLH transcription factors on chromatin. It also locked cells into a “mitotic stem cell” transcriptional state resembling the pluripotent program of embryonic stem cells. The substrates of APCCDH1 SKP2 and Cyclin B1 share with ID2 the phosphorylation-dependent, D-box-independent interaction with core APC. These results reveal a new layer of control of the mechanism by which substrates are recognized by APC.


  • Open Access

    Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes

    by Timothy Cardozo, Lila Cardozo, Mohamed Boutjdir

    Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of aAb to self-antigen and subsequent tissue damage. Here, we review the known decoy molecules of these types, discuss newer technological opportunities afforded by monoclonal antibody and structural biology advances, and discuss the challenges to this approach. Recent opportunities relevant to this approach for cardiac phenotypes, specifically Ro-associated long QT syndrome, are discussed.


  • Open Access

    Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease

    by Timothy Cardozo, Ronald Veazey

    Aims of the study Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID‐19 vaccines could worsen disease upon exposure to challenge or circulating virus. Methods used to conduct the study Published literature was reviewed to identify preclinical and clinical evidence that COVID‐19 vaccines could worsen disease upon exposure to challenge or circulating virus. Clinical trial protocols for COVID‐19 vaccines were reviewed to determine if risks were properly disclosed. Results of the study COVID‐19 vaccines designed to elicit neutralizing antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralizing antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID‐19 disease via antibody‐dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID‐19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials. Conclusions drawn from the study and clinical implications The specific and significant COVID‐19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.


  • Open Access

    Translational induction of ATF4 during integrated stress response requires noncanonical initiation factors eIF2D and DENR

    by Deepika Vasudevan, Sarah D. Neuman, Amy Yang, Lea Lough, Brian Brown, Arash Bashirullah, Timothy Cardozo, Hyung Don Ryoo

    The Integrated Stress Response (ISR) helps metazoan cells adapt to cellular stress by limiting the availability of initiator methionyl-tRNA for translation. Such limiting conditions paradoxically stimulate the translation of ATF4 mRNA through a regulatory 5′ leader sequence with multiple upstream Open Reading Frames (uORFs), thereby activating stress-responsive gene expression. Here, we report the identification of two critical regulators of such ATF4 induction, the noncanonical initiation factors eIF2D and DENR. Loss of eIF2D and DENR in Drosophila results in increased vulnerability to amino acid deprivation, susceptibility to retinal degeneration caused by endoplasmic reticulum (ER) stress, and developmental defects similar to ATF4 mutants. eIF2D requires its RNA-binding motif for regulation of 5′ leader-mediated ATF4 translation. Consistently, eIF2D and DENR deficient human cells show impaired ATF4 protein induction in response to ER stress. Altogether, our findings indicate that eIF2D and DENR are critical mediators of ATF4 translational induction and stress responses in vivo.